SHP099

ArtNr	HY-100388-5mg
Hersteller	MedChem Express
CAS-Nr.	1801747-42-1
Menge	5 mg
Quantity options	100 mg 10mM/1mL 10 mg 1mg 50 mg 5 mg
Kategorie	Neuroscience Neural Signaling Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.80
Formula	C16H19Cl2N5
Citations	ACS Nano. 2023 Aug 14.<br/>Acta Pharm Sin B. 11 August 2021.<br/>Acta Pharm Sin B. 17 February 2022.<br/>Acta Pharm Sin B. 2024 Mar 18.<br/>Ann Transl Med. 2020 Dec;8(23):1570.<br/>Biochem Biophys Res Commun. 2023 Jul 20.<br/>Biochem Biophys Res Commun. 2024 Mar 26, 149812.<br/>bioRxiv. 2019 Sep.<br/>bioRxiv. 2024 Feb 5.<br/>Br J Cancer. 2022 Dec 7.<br/>Brain Pathol. 2020 Mar;30(2):373-385.<br/>Cancer Cell Int. 2021 Jul 3;21(1):337.<br/>Cancer Res Commun. August 17 2022.<br/>Cancer Res. 2021 Apr 5;canres.3738.2020.<br/>Cancers (Basel). 2022 May 12;14(10):2377.<br/>Cell Rep. 2019 Aug 27;28(9):2331-2344.e8.<br/>Cell Syst. 2020 Nov 18;11(5):478-494.e9.<br/>Commun Biol. 2020 Mar 17;3(1):128. <br/>Exp Cell Res. 2022 Sep 21;113361.<br/>Exp Mol Med. 2020 Jun;52(6):911-920.<br/>Exp Ther Med. February 22, 2022.<br/>FEBS Open Bio. 2020 Dec;10(12):2578-2587.<br/>Front Immunol. 21 January 2021.<br/>Hematol Oncol. 2023 Oct 24.<br/>Hepatology. 2018 Jul;68(1):333-348.<br/>Hepatology. 2020 Jul;72(1):155-168. <br/>Inflamm Res. 2023 Jun 23.<br/>J Exp Med. 2022 Apr 4;219(4):e20210739.<br/>J Immunol Res. 2020 Jun 19;2020:4598476.<br/>J Immunol. 2021 Sep 1;207(5):1419-1427.<br/>J Orthop Translat. 2022 Feb 17;32:112-120.<br/>MedComm. 04 March 2022.<br/>Microvasc Res. 2022 Jun 4;104397.<br/>Mol Cell. 2021 Oct 7;81(19):4076-4090.e8.<br/>Mol Med. 2024 Apr 9;30(1):47.<br/>Nat Commun. 2019 Apr 1;10(1):1473. <br/>Nat Commun. 2018 Oct 30;9(1):4507. <br/>Nat Immunol. 2021 Oct 22.<br/>Neural Regen Res. 2024 May 17.<br/>Neural Regen Res. 2025 Mar 1;20(3):858-872.<br/>Neuro Oncol. 2019 Nov 4;21(11):1423-1435. <br/>Patent. US20190231805A1.<br/>Patent. US20220380385A1.<br/>Research Square Preprint. 2021 Apr.<br/>Research Square Preprint. 2021 Mar.<br/>Sci Rep. 2023 Jun 20;13(1):10041.<br/>Signal Transduct Target Ther. 2022 Sep 12;7(1):317.<br/>SSRN. 2020 May.<br/>Theranostics. 2021 Jan 1;11(2):555-566.<br/>Thromb Res. 2023Jun 5.<br/>Acta Pharm Sin B. 11 August 2021.<br/>Cancer Discov. 2018 Oct;8(10):1237-1249. <br/>Cancer Res Commun. 2023 Nov 30.<br/>Cancer Res. 2020 Aug 15;80(16):3413-3423.<br/>Inflammation. 2021 Feb 24.<br/>Open Biol. 2017 May;7(5). pii: 170066.<br/>Patent. US20200330595A1.<br/>[1]Garcia Fortanet J, et al. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor. J Med Chem. 2016 Sep 8;59(17):7773-82.<br/>[2]Chen YN, et al. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases. Nature. 2016 Jul 7;535(7610):148-52.
Smiles	NC1=NC(N2CCC(C)(N)CC2)=CN=C1C3=CC=CC(Cl)=C3Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1801747-42-1
Lieferbar
Product Description	SHP099 is a potent, selective, orally available SHP2 inhibitor with an IC50 of 70 nM[1].
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	352.26
Clinical Information	No Development Reported
Manufacturers Research Area	Cancer
Solubility	DMSO : 12 mg/mL (ultrasonic)\|H2O : < 0.1 mg/mL (ultrasonic)
Target	Phosphatase; SHP2
Manufacturers Target	Phosphatase; SHP2
Manufacturers Pathway	Metabolic Enzyme/Protease; Protein Tyrosine Kinase/RTK
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-100388-5mg-safety-datasheet.pdf